1. Home
  2. SLN vs HBCP Comparison

SLN vs HBCP Comparison

Compare SLN & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$11.51

Market Cap

678.0M

Sector

Health Care

ML Signal

HOLD

Logo Home Bancorp Inc.

HBCP

Home Bancorp Inc.

HOLD

Current Price

$67.17

Market Cap

546.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
HBCP
Founded
1994
1908
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
678.0M
546.5M
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
SLN
HBCP
Price
$11.51
$67.17
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$42.60
$65.50
AVG Volume (30 Days)
647.9K
50.3K
Earning Date
05-07-2026
04-20-2026
Dividend Yield
N/A
1.98%
EPS Growth
N/A
29.01
EPS
N/A
2.93
Revenue
$559,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.97
P/E Ratio
N/A
$23.25
Revenue Growth
N/A
N/A
52 Week Low
$4.19
$50.54
52 Week High
$17.58
$74.50

Technical Indicators

Market Signals
Indicator
SLN
HBCP
Relative Strength Index (RSI) 42.56 N/A
Support Level $4.70 N/A
Resistance Level $15.28 N/A
Average True Range (ATR) 0.58 0.00
MACD -0.23 0.00
Stochastic Oscillator 10.46 0.00

Price Performance

Historical Comparison
SLN
HBCP

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About HBCP Home Bancorp Inc.

Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.

Share on Social Networks: